Search for:
Enter your search term above.
About
About LCRF
People
Board of Directors
Scientific Advisory Board
Research Advocates
Education & Engagement Committee
Staff
Research partners
Financials
Careers
Press kit
Get Involved
Events calendar
Free to Breathe
Gala
Together Separately livestreams
Honor a memory
Financial giving
Donate
Other ways to give
What your gift can do
Let's connect!
Resources
How we can help you
Support line (844) 835-4325
Print and digital resources
Recursos en español
Together Separately livestreams
Lung cancer facts
Know Your Risk
Women + Lung Cancer
Symptoms
Living with Lung Cancer
Biomarker Testing
Clinical trials
Quick links
Lung cancer journeys
Share your story
Research
Why research?
Our investigators
Current funded projects
Research funding opportunities
Scientific updates
Lung Cancer Mutation Consortium
News
Close
Link back to homepage
Link back to homepage
About
About LCRF
People
Board of Directors
Scientific Advisory Board
Research Advocates
Education & Engagement Committee
Staff
Research partners
Financials
Careers
Press kit
Get Involved
Events calendar
Free to Breathe
Gala
Together Separately livestreams
Honor a memory
Financial giving
Donate
Other ways to give
What your gift can do
Let’s connect!
Resources
How we can help you
Support line (844) 835-4325
Print and digital resources
Recursos en español
Together Separately livestreams
Lung cancer facts
Know Your Risk
Women + Lung Cancer
Symptoms
Living with Lung Cancer
Biomarker Testing
Clinical trials
Quick links
Lung cancer journeys
Share your story
Research
Why research?
Our investigators
Current funded projects
Research funding opportunities
Scientific updates
Lung Cancer Mutation Consortium
News
In Honor
Subscribe
Give Now
Link to Open Side Menu
News: ERBB2
Home
/
News
/
ERBB2
Refine Your Search
Categories
Categories
Announcements
Awareness
Education
Events
Fundraising
Grants
In the News
Journeys
Partnerships
People
Remembering
Research
Science Made Simple
Science Team Updates
SCLC
Uncategorized
Women & Lung Cancer
Zongertinib approved as first-line HER2+ lung cancer treatment
April 24, 2026
